Treatment Care Pathways of Four Patients with Metastatic Gastro-Oesophageal Cancer in the United Kingdom (UK), Utilising Trifluridine/Tiparicil
Metastatic gastro-oesophageal cancer outcomes remain poor despite advances in systemic treatment. Clinical deterioration if often rapid and uncontrolled symptoms can affect quality of life. Trifluridine/tiparicil was approved in 3rd line setting after it demonstrated superior median survival compared to placebo. Although treatment is beneficial, not all patients respond to treatment. Here we present treatment journey of 4 patients who have previously received at least 2 lines of palliative systemic therapy, treated in two hospitals in the United Kingdom. We also use clinical parameters to retrospectively determine prognosis based on published clinical prognostic scores.
